{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:01:25Z","timestamp":1781715685266,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011421","name":"Sanofi China Investment Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011421","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>This is the first phase 4 study evaluating safety and efficacy of enzyme replacement therapy (ERT) in Chinese patients with Fabry disease, and exploring the impact of COVID-19 infection on the prognosis of Fabry disease under ERT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods and results<\/jats:title>\n            <jats:p>Eligible patients received an infusion of agalsidase beta (1.0\u00a0mg\/kg\/2w) for up to 48\u00a0weeks. The primary endpoint was the safety of agalsidase beta. The endpoints of efficacy included changes in plasma globotriaosylceramide (GL-3), globotriaosylsphingosine (Lyso-GL-3), symptoms and estimated glomerular filtration rate (eGFR) from baseline to week 48. A post-hoc subgroup analysis was conducted by age group (&lt;\u200930\u00a0years and\u2009\u2265\u200930\u00a0years) and in patients with or without COVID-19 infection. All 22 patients completed the study and 14 of them were infected by COVID-19. Treatment-related adverse events (AEs) and infusion-associated reactions (IARs) were reported in 8 participants (36.4%). Mean plasma GL-3 (-34.6%) and Lyso-GL-3 (-60.3%) levels decreased from baseline to week 48. Thirteen participants (59.1%) experienced improved specific symptoms at week 48. There were no meaningful changes in eGFR during the study, and the overall population showed an annual eGFR slope of 0.43\u00a0mL\/min\/1.73 m<jats:sup>2<\/jats:sup>\/year (95% CI: -5.95\u00a0to\u00a06.82). In the subgroup analysis, the reductions in plasma GL-3 and Lyso-GL-3 levels, improvement in symptoms, and attenuation of eGFR decline after 48\u00a0weeks of treatment were generally greater in patients aged\u2009&lt;\u200930\u00a0years (n\u2009=\u200911) than in patients aged\u2009\u2265\u200930\u00a0years (n\u2009=\u200911), and less pronounced in the COVID-19 infected group (n\u2009=\u200914) than in the uninfected group (n\u2009=\u20098).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study demonstrates that agalsidase beta is safe and effective in Chinese patients with Fabry disease, and suggestes that COVID-19 infection may potentially impact the renal prognosis for Fabry disease.<\/jats:p>\n            <jats:p>Trial registration: ClinicalTrials.gov, NCT05054387. Registered 09 September 2021, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05054387\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/study\/NCT05054387<\/jats:ext-link>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03950-7","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T19:10:29Z","timestamp":1754334629000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A phase 4, open-label, multicenter study of the safety and efficacy of agalsidase beta in Chinese patients with Fabry disease"],"prefix":"10.1186","volume":"20","author":[{"given":"Hong","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7388-6339","authenticated-orcid":false,"given":"Nan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"issue":"2","key":"3950_CR1","doi-asserted-by":"publisher","first-page":"683","DOI":"10.21037\/cdt-20-743","volume":"11","author":"D Oder","year":"2021","unstructured":"Oder D, M\u00fcntze J, Nordbeck P. Contemporary therapeutics and new drug developments for treatment of Fabry disease: a narrative review. Cardiovasc Diagn Ther. 2021;11(2):683\u201395.","journal-title":"Cardiovasc Diagn Ther"},{"issue":"5","key":"3950_CR2","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.3390\/jcm12052063","volume":"12","author":"G Bertoldi","year":"2023","unstructured":"Bertoldi G, Caputo I, Driussi G, Stefanelli LF, Di Vico V, Carraro G, et al. Biochemical mechanisms beyond glycosphingolipid accumulation in Fabry Disease: might they provide additional therapeutic treatments? J Clin Med. 2023;12(5):2063.","journal-title":"J Clin Med"},{"issue":"1\u20132","key":"3950_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ymgme.2022.07.010","volume":"137","author":"DP Germain","year":"2022","unstructured":"Germain DP, Altarescu G, Barriales-Villa R, Mignani R, Pawlaczyk K, Pieruzzi F, et al. An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease. Mol Genet Metab. 2022;137(1\u20132):49\u201361.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3950_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12882-023-03138-w","volume":"24","author":"W Guo","year":"2023","unstructured":"Guo W, Xie Y, Ji P, Li S, Cai G, Chen X. The evolution of the initial manifestations and renal involvement of Chinese patients with classical and late-onset Fabry disease at different sexes and ages. BMC Nephrol. 2023;24(1):90.","journal-title":"BMC Nephrol"},{"issue":"5","key":"3950_CR5","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2016090964","volume":"28","author":"M Arends","year":"2017","unstructured":"Arends M, Wanner C, Hughes D, Mehta A, Oder D, Watkinson OT, et al. Characterization of classical and nonclassical Fabry disease: a multicenter study. J Am Soc Nephrol. 2017;28(5):1631\u201341.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"3950_CR6","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123(4):416\u201327.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"3950_CR7","first-page":"321","volume":"60","author":"Chinese Fabry Disease Expert Panel","year":"2021","unstructured":"Chinese Fabry Disease Expert Panel. Expert consensus for diagnosis and treatment of Fabry disease in China (2021). Chin J Intern Med. 2021;60(4):321\u201330.","journal-title":"Chin J Intern Med"},{"issue":"1","key":"3950_CR8","first-page":"91","volume":"130","author":"M Nowicki","year":"2020","unstructured":"Nowicki M, Bazan-Socha S, B\u0142a\u017cejewska-Hyzorek B, Gellert R, Imiela J, Ka\u017amierczak J, et al. Enzyme replacement therapy in Fabry disease in Poland: a position statement. Pol Arch Intern Med. 2020;130(1):91\u20137.","journal-title":"Pol Arch Intern Med"},{"issue":"2","key":"3950_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ymgme.2015.10.007","volume":"117","author":"RJ Hopkin","year":"2016","unstructured":"Hopkin RJ, Jefferies JL, Laney DA, Lawson VH, Mauer M, Taylor MR, et al. The management and treatment of children with Fabry disease: a United States-based perspective. Mol Genet Metab. 2016;117(2):104\u201313.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"3950_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","volume":"124","author":"C Wanner","year":"2018","unstructured":"Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, et al. European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab. 2018;124(3):189\u2013203.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3950_CR11","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.bbadis.2010.09.007","volume":"1812","author":"MJ van Breemen","year":"2011","unstructured":"van Breemen MJ, Rombach SM, Dekker N, Poorthuis BJ, Linthorst GE, Zwinderman AH, et al. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. Biochim Biophys Acta. 2011;1812(1):70\u20136.","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"3950_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173358","volume":"12","author":"R El Dib","year":"2017","unstructured":"El Dib R, Gomaa H, Ortiz A, Politei J, Kapoor A, Barreto F. Enzyme replacement therapy for Anderson-Fabry disease: a complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies. PLoS ONE. 2017;12(3): e0173358.","journal-title":"PLoS ONE"},{"issue":"4","key":"3950_CR13","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.gpb.2021.08.001","volume":"19","author":"T Chen","year":"2021","unstructured":"Chen T, Chen X, Zhang S, Zhu J, Tang B, Wang A, et al. The genome sequence archive family: toward explosive data growth and diverse data types. Genom Proteomics Bioinf. 2021;19(4):578\u201383.","journal-title":"Genom Proteomics Bioinf"},{"issue":"D1","key":"3950_CR14","doi-asserted-by":"publisher","first-page":"D27","DOI":"10.1093\/nar\/gkab951","volume":"50","author":"CNCB-NGDC Members and Partners","year":"2022","unstructured":"CNCB-NGDC Members and Partners. Database Resources of the National Genomics Data Center, China National Center for Bioinformation in 2022. Nucleic Acids Res. 2022;50(D1):D27\u201338.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"3950_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","volume":"367","author":"LA Inker","year":"2012","unstructured":"Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin c. N Engl J Med. 2012;367(1):20\u20139.","journal-title":"N Engl J Med"},{"issue":"3","key":"3950_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Mu\u00f1oz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20(3):629\u201337.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"3950_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","volume":"146","author":"M Banikazemi","year":"2007","unstructured":"Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med. 2007;146(2):77\u201386.","journal-title":"Ann Intern Med"},{"issue":"5","key":"3950_CR18","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1681\/ASN.2006080816","volume":"18","author":"DP Germain","year":"2007","unstructured":"Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol. 2007;18(5):1547\u201357.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"3950_CR19","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ymgme.2012.12.005","volume":"108","author":"BE Smid","year":"2013","unstructured":"Smid BE, Hoogendijk SL, Wijburg FA, Hollak CE, Linthorst GE. A revised home treatment algorithm for Fabry disease: influence of antibody formation. Mol Genet Metab. 2013;108(2):132\u20137.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3950_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry\u2019s disease. N Engl J Med. 2001;345(1):9\u201316.","journal-title":"N Engl J Med"},{"issue":"1","key":"3950_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22010206","volume":"22","author":"O Azevedo","year":"2020","unstructured":"Azevedo O, Gago MF, Miltenberger-Miltenyi G, Sousa N, Cunha D. Fabry disease therapy: state-of-the-art and current challenges. Int J Mol Sci. 2020;22(1): 206.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3950_CR22","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jpeds.2007.09.007","volume":"152","author":"JE Wraith","year":"2008","unstructured":"Wraith JE, Tylki-Szymanska A, Guffon N, Lien YH, Tsimaratos M, Vellodi A, et al. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr. 2008;152(4):563\u201370.","journal-title":"J Pediatr"},{"issue":"5","key":"3950_CR23","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/jmedgenet-2017-104863","volume":"55","author":"M Arends","year":"2018","unstructured":"Arends M, Biegstraaten M, Wanner C, Sirrs S, Mehta A, Elliott PM, et al. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study. J Med Genet. 2018;55(5):351\u20138.","journal-title":"J Med Genet"},{"issue":"3","key":"3950_CR24","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ymgme.2011.12.006","volume":"105","author":"WR Wilcox","year":"2012","unstructured":"Wilcox WR, Linthorst GE, Germain DP, Feldt-Rasmussen U, Waldek S, Richards SM, et al. Anti-\u03b1-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry. Mol Genet Metab. 2012;105(3):443\u20139.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3950_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13023-024-03049-5","volume":"19","author":"R Mignani","year":"2024","unstructured":"Mignani R, Americo C, Aucella F, Battaglia Y, Cianci V, Sapuppo A, et al. Reducing agalsidase beta infusion time in Fabry patients: low incidence of antibody formation and infusion-associated reactions in an Italian multicenter study. Orphanet J Rare Dis. 2024;19(1):38.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"3950_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.107585","volume":"139","author":"A Burlina","year":"2023","unstructured":"Burlina A, Brand E, Hughes D, Kantola I, Kr\u04d3mer J, Nowak A, et al. An expert consensus on the recommendations for the use of biomarkers in Fabry disease. Mol Genet Metab. 2023;139(2): 107585.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"3950_CR27","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/j.1399-0004.2012.01947.x","volume":"83","author":"L Borgwardt","year":"2013","unstructured":"Borgwardt L, Feldt-Rasmussen U, Rasmussen AK, Ballegaard M, Meldgaard Lund A. Fabry disease in children: agalsidase-beta enzyme replacement therapy. Clin Genet. 2013;83(5):432\u20138.","journal-title":"Clin Genet"},{"issue":"2","key":"3950_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2022.106967","volume":"138","author":"RJ Hopkin","year":"2023","unstructured":"Hopkin RJ, Cabrera GH, Jefferies JL, Yang M, Ponce E, Brand E, et al. Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: an analysis from the Fabry Registry. Mol Genet Metab. 2023;138(2): 106967.","journal-title":"Mol Genet Metab"},{"issue":"8","key":"3950_CR29","doi-asserted-by":"publisher","first-page":"sfae194","DOI":"10.1093\/ckj\/sfae194","volume":"17","author":"JL Batista","year":"2024","unstructured":"Batista JL, Hariri A, Maski M, Richards S, Gudivada B, Raynor LA, et al. Reduction in kidney function decline and risk of severe clinical events in agalsidase beta-treated Fabry disease patients: a matched analysis from the Fabry Registry. Clin Kidney J. 2024;17(8):sfae194. https:\/\/doi.org\/10.1093\/ckj\/sfae194.","journal-title":"Clin Kidney J"},{"key":"3950_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1750-1172-8-47","volume":"8","author":"SM Rombach","year":"2013","unstructured":"Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis. 2013;8:47.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3950_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12771","volume":"48","author":"DA Hughes","year":"2025","unstructured":"Hughes DA, Sunder-Plassmann G, Jovanovic A, Brand E, West ML, Bichet DG, et al. Renal and multisystem effectiveness of 3.9 years of migalastat in a global real-world cohort: results from the followme Fabry pathfinders registry. J Inherit Metab Dis. 2025;48(1): e12771.","journal-title":"J Inherit Metab Dis"},{"key":"3950_CR32","first-page":"85","volume":"12","author":"D Concolino","year":"2017","unstructured":"Concolino D, Amico L, Cappellini MD, Cassinerio E, Conti M, Donati MA, et al. Home infusion program with enzyme replacement therapy for Fabry disease: the experience of a large Italian collaborative group. Mol Genet Metab Rep. 2017;12:85\u201391.","journal-title":"Mol Genet Metab Rep"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03950-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03950-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03950-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T16:23:02Z","timestamp":1757348582000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03950-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3950"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03950-7","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"15 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were reviewed and approved by Ruijin Hospital Ethics Committee, Shanghai Jiao\u00a0Tong University School of Medicine (approval date: 3 March 2021, reference number: N-2021-17), Clinical Research Ethics Committees of Peking University First Hospital (approval date: 8 November 2021, reference number: No. 2021 Science 091), Ethics Committee of the First Hospital of Shanxi Medical University (approval date: 20 April 2021, reference number: 2021, ethics number 47), Ethics Committee of Children\u2019s Hospital of Fudan University (approval date: 13 April 2021, reference number: 2021-230), Peking Union Medical College Hospital Ethics Review Committee (approval date: 13 June 2021, reference number: KS2021318), Medical Ethics Committee of Tongji Hospital (approval date: 31 March 2021, reference number: TJ-IRB202148). Written informed consent to participate in this study was provided by the participants\u2019 legal guardian\/next of kin.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of this study was provided by the participants\u2019 legal guardian\/next of kin. Written informed consent was obtained from the minor(s)\u2019 legal guardian\/next of kin for the publication of any potentially identifiable images or data included in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"B.L., Q.F. and S.L. were employed by Sanofi and hold stocks of Sanofi. H.R., W.Z. (Beijing), Y.O., J.G., H.X., J.M., X.L., X.P., Y.Y., W.Z. (Taiyuan), Q.S. and N.C. declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"401"}}